Skip to main content

Maxcyte, Inc.

MXCT
Exchange
Nasdaq
Industry
Services-Commercial Physical & Biological Research
SEC CIK
0001287098

In the last 90 days, Maxcyte, Inc. insiders filed 1 open-market purchase and 0 sales; 118 institutions reported holding it in 13F filings for Q3 2026, worth $72.6M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 18, 2026
$129.1M
Insider buysLast 90 days, $120.8K in total
1
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, −4 vs. previous quarter
118
13F valueReported value at the end of Q3 2026
$72.6M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$33.0M
−14.5% year over year
Net income, FY2025
-$44.6M
No comparable prior period
Free cash flow, FY2025
-$36.2M
No comparable prior period
Revenue, Q3 FY2026
$10.2M
+48.7% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $44.6M (135.1% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
1.58M
Shares sold short
Change
−248.6K
−13.6% vs. previous
Days to cover
1.34
At average daily volume

Superinvestors holding MXCT, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding MXCT at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Maxcyte, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 18, 2026 (view filing)4:38 PM ETNov 171 dayMasoud MaherPresident and CEOPPurchase+100.0K$1.21+$120.8K+21.1%575.0K after
Mar 19, 2026 (view filing)Mar 172 daysSwirsky Douglas JCHIEF FINANCIAL OFFICERSSale−10.1K$0.82−$8.32K−6.3%151.7K after
Aug 27, 2025 (view filing)Jun 2563 daysLateHemrajani RekhaDirectorSSale−10.7K$2.09−$22.3K−21.1%39.9K after10b5-1
Aug 13, 2025 (view filing)Aug 13Same daySwirsky Douglas JCHIEF FINANCIAL OFFICERPPurchase+50.0K$1.29+$64.5K+44.7%161.8K after
Aug 13, 2025 (view filing)Aug 13Same dayMasoud MaherPresident and CEOPPurchase+75.0K$1.37+$102.8K+75.0%175.0K after
Aug 13, 2025 (view filing)Aug 13Same dayErck Stanley CDirectorPPurchase+100.0K$1.37+$137.0K+33.5%398.3K after
Aug 13, 2025 (view filing)Aug 13Same dayDouglas RichardDirectorPPurchase+80.0K$1.39+$111.2K+53.1%230.6K after
Aug 13, 2025 (view filing)Aug 13Same dayBrooke William WDirectorPPurchase+50.0K$1.29+$64.5K+49.6%150.9K after
Mar 20, 2025 (view filing)Mar 182 daysSoleymannezhad AliChief Commercial OfficerSSale−1.21K$3.18−$3.85K−2.0%59.4K after
Mar 20, 2025 (view filing)Mar 182 daysSandoval David I.GENERAL COUNSELSSale−353$3.18−$1.12K−0.5%64.2K after

Top 10 13F holders, Q3 2026

See all 118 holders

The largest institutional positions in Maxcyte, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding MXCT in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Capricorn Fund Managers Ltd8,200,000$9.18M0.87%00.0%Unchanged
Vitruvian Partners LLP5,043,356$5.65M4.99%00.0%Unchanged
Liontrust Investment Partners LLP4,840,487$5.42M0.08%+4,840,487New
Vanguard Capital Management LLC4,008,963$4.49M0.00%−22,321−0.6%Reduced
Morgan Stanley3,981,178$4.46M0.00%+287,129+7.8%Added
BlackRock, Inc.3,026,506$3.39M0.00%−34,454−1.1%Reduced
BNP PARIBAS ASSET MANAGEMENT Holding S.A.2,773,554$3.11M0.00%00.0%Unchanged
Cadian Capital Management, LP2,624,685$2.94M0.25%+423,519+19.2%Added
Two Sigma Investments, LP2,409,859$2.70M0.00%+946,918+64.7%Added
Mudita Advisors LLP2,260,201$2.53M0.58%−1,110,488−32.9%Reduced

Holders of 5% or more of MXCT

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Maxcyte, Inc..

Largest holders of MXCT from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Capricorn Fund Managers Ltd13G7.70%8.20M sharesNewFeb 5, 20261 filingFeb 5, 2026SEC